Sandeep Singh, MD
Cardiovascular Disease · Mesquite, TXNPI 1821260670
Payments from drug & device makers
Across 82 payments — averaging $21.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$402
- Novartis$136
- Novo Nordisk$128
- Abiomed$123
- Amgen$101
- E.r. Squibb & Sons, L.L.C.$83
- plus $797 from 19 others
What the payments were for
- Food & beverage$1,75899%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 19 | $402 |
| Novartis | 7 | $136 |
| Novo Nordisk | 6 | $128 |
| Abiomed | 1 | $123 |
| Amgen | 6 | $101 |
| E.r. Squibb & Sons, L.L.C. | 5 | $83 |
| Amarin Pharma, Inc. | 5 | $79 |
| Pfizer | 4 | $73 |
| Inspire Medical Systems, Inc. | 1 | $70 |
| AstraZeneca | 4 | $70 |
| Scpharmaceuticals Inc. | 3 | $67 |
| Johnson & Johnson | 4 | $56 |
| Philips North America LLC | 1 | $53 |
| Shockwave Medical, Inc | 1 | $43 |
| Lexicon Pharmaceuticals, Inc. | 2 | $38 |
| Boehringer Ingelheim | 2 | $37 |
| Abbott | 2 | $36 |
| Genentech USA, Inc. | 2 | $32 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $28 |
| Actelion Pharmaceuticals US, Inc. | 1 | $27 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $26 |
| Heartflow, Inc. | 1 | $22 |
| Cvrx, Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $13 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$123
How this compares
$1,771 in reported general payments places this provider in the 30th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 228 | $251,034 |
| EntrestoSacubitril/Valsartan | 120 | $137,625 |
| MounjaroTirzepatide | 106 | $128,978 |
| FarxigaDapagliflozin Propanediol | 72 | $83,652 |
| XareltoRivaroxaban | 48 | $54,173 |
| OzempicSemaglutide | 46 | $53,216 |
| JardianceEmpagliflozin | 41 | $46,808 |
| Repatha SureclickEvolocumab | 29 | $22,495 |
| Repatha PushtronexEvolocumab | 11 | $6,354 |
| Praluent PenAlirocumab | 13 | $6,025 |
| Metoprolol Succinate | 233 | $3,610 |
| Ranolazine ErRanolazine | 32 | $2,971 |
| Ezetimibe | 132 | $2,764 |
| Atorvastatin Calcium | 269 | $2,615 |
| Bisoprolol Fumarate | 100 | $2,260 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $73 | $251,034228 claims |
| NovartisEntresto | $136 | $137,625120 claims |
| AstraZenecaFarxiga | $70 | $83,65272 claims |
| Johnson & JohnsonXarelto | $56 | $54,17348 claims |
| Novo NordiskOzempic | $128 | $53,21646 claims |
| Boehringer IngelheimJardiance | $37 | $46,80841 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Mesquite
- Ramin Farzaneh-FarDallas$17.1M
- Jeffrey GladdenDallas$15.8M
- Ann NavarDallas$14.5M
- David BrabhamAmarillo$11.5M
- Justin GrodinDallas$6.2M
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- Faisal WahidMcKinney$3.4M
- James FeldmanHouston$3.1M
- Fernando BoccalandroOdessa$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.